Biora Therapeutics, Inc. (BIOR)

NASDAQ: BIOR · IEX Real-Time Price · USD
4.05
+0.13 (3.32%)
Feb 6, 2023, 1:24 PM EST - Market open
3.32%
Market Cap 36.76M
Revenue (ttm) 726,000
Net Income (ttm) -117.31M
Shares Out 9.10M
EPS (ttm) -14.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 495,361
Open 3.94
Previous Close 3.92
Day's Range 3.86 - 4.30
52-Week Range 1.95 - 52.75
Beta 1.06
Analysts Buy
Price Target 84.15 (+1,977.78%)
Earnings Date Mar 27, 2023

About BIOR

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2020
Employees 124
Stock Exchange NASDAQ
Ticker Symbol BIOR
Full Company Profile

Financial Performance

In 2021, BIOR's revenue was $1.25 million, an increase of 669.75% compared to the previous year's $162,000. Losses were -$247.41 million, 28.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BIOR stock is "Buy." The 12-month stock price forecast is $84.15, which is an increase of 1,977.78% from the latest price.

Price Target
$84.15
(1,977.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Biora Therapeutics, Inc. (BIOR), indicating that the stock has found support. This, combined with an upward trend in earnings...

4 days ago - Zacks Investment Research

Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn's & Colitis Congress

Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration Study demonstrates targeted delivery devices functioned ...

2 weeks ago - GlobeNewsWire

Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?

Biora Therapeutics (NASDAQ: BIOR) stock is on the rise Wednesday following news of feedback from the FDA. Today's news concerns the company's Targeted Therapeutics Platform and PGN-600 program for th...

3 weeks ago - InvestorPlace

Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023

Company is on track to move into the clinic with its lead targeted therapeutics program Company is on track to move into the clinic with its lead targeted therapeutics program

1 month ago - GlobeNewsWire

Biora Therapeutics Announces Reverse Stock Split

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split...

1 month ago - GlobeNewsWire

Biora Therapeutics Announces Two Poster Presentations at the Crohn's & Colitis Congress

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenti...

2 months ago - GlobeNewsWire

Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development

Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora The...

2 months ago - GlobeNewsWire

Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates

Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

2 months ago - Zacks Investment Research

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients

2 months ago - GlobeNewsWire

Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report third quarter en...

3 months ago - GlobeNewsWire

Biora Therapeutics Announces $9.75 Million Direct Offering

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitiv...

3 months ago - GlobeNewsWire

Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset sa...

3 months ago - GlobeNewsWire

Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients

Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical Coverage Throughout Portion of Colon Implicated in Patients with Active Ulcerative Colitis Data Pr...

3 months ago - GlobeNewsWire

Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022

Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform

3 months ago - GlobeNewsWire

Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Further Demonstrating Possibilities for Systemic Delivery of Large Molecules Further Demonstrating Possibilities for Systemic Delivery of Large Molecules

3 months ago - GlobeNewsWire

Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference

SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the company will participate in the 12t...

4 months ago - GlobeNewsWire

Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists

Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small Intestine for Treatment of Any Disease Including Type 2 Diabetes Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small I...

5 months ago - GlobeNewsWire

Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board...

5 months ago - GlobeNewsWire

Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company's management team will be ...

5 months ago - GlobeNewsWire

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients

6 months ago - GlobeNewsWire

Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform

All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis

6 months ago - GlobeNewsWire

Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended Jun...

6 months ago - GlobeNewsWire

Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for present...

6 months ago - GlobeNewsWire

Biora Therapeutics to Participate in Upcoming BTIG Investment Conference

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company's management team will be p...

6 months ago - GlobeNewsWire

Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022

Demonstrates OBDS Device Performance and Bioavailability in Animal Models Demonstrates OBDS Device Performance and Bioavailability in Animal Models

7 months ago - GlobeNewsWire